Treatment of Primary Aldosteronism with mTORC1 Inhibitors.

CONTEXT mTORC1 activity is often increased in the adrenal cortex of patients with primary aldosteronism and mTORC1 inhibition decreases aldosterone production in adrenocortical cells, suggesting the mTORC1 pathway as a possible target for treatment of primary aldosteronism. OBJECTIVE To investigate the effect of mTORC1 inhibition on adrenal steroid hormones and hemodynamic parameters in mice and in patients with primary aldosteronism. DESIGN (i) Plasma aldosterone, corticosterone and angiotensin II were measured in mice treated for 24 hours with vehicle or rapamycin. (ii) Plasma aldosterone levels after a saline infusion test, plasma renin, 24-hour urine steroid hormone metabolome and hemodynamic parameters were measured during an open-label study in 12 patients with primary aldosteronism before and after two-weeks of treatment with everolimus and after a two-week washout period. MAIN OUTCOME MEASURES (i) Change in plasma aldosterone levels. (ii) Change in other steroid hormones, renin, angiotensin II and hemodynamic parameters. RESULTS Treatment of mice with rapamycin significantly decreased plasma aldosterone levels (P = 0.007). Overall, treatment of primary aldosteronism patients with everolimus significantly decreased blood pressure (P < 0.05) and increased renin levels (P = 0.001) but did not lead to a significant reduction in aldosterone levels. However, prominent reduction of aldosterone levels upon everolimus treatment was observed in 4 out of 12 patients. CONCLUSION In mice, mTORC1 inhibition was associated with reduced plasma aldosterone levels. In patients with primary aldosteronism, mTORC1 inhibition was associated with improved blood pressure and renin suppression. In addition, mTORC1 inhibition appeared to reduce plasma aldosterone in a subset of patients.

[1]  F. Beuschlein,et al.  Proteomic Landscape of Aldosterone-Producing Adenoma , 2019, Hypertension.

[2]  J. Lenders,et al.  Prevalence of primary aldosteronism in primary care: a cross-sectional study. , 2018, The British journal of general practice : the journal of the Royal College of General Practitioners.

[3]  G. Curhan,et al.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. , 2018, The lancet. Diabetes & endocrinology.

[4]  Fiorenzo Gaita,et al.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. , 2018, The lancet. Diabetes & endocrinology.

[5]  K. Okamura,et al.  Molecular characteristics of the KCNJ5 mutated aldosterone-producing adenomas. , 2017, Endocrine-related cancer.

[6]  D. Sabatini,et al.  The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway. , 2017, Cell metabolism.

[7]  D. Grimm,et al.  Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma , 2017, International journal of molecular sciences.

[8]  R. Lifton,et al.  Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma , 2017, The Journal of clinical investigation.

[9]  S. Rudaz,et al.  Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids. , 2017, Toxicology.

[10]  F. Veglio,et al.  Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. , 2017, Journal of the American College of Cardiology.

[11]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[12]  Long term outcome of Aldosteronism after target treatments , 2016, Scientific reports.

[13]  W. Young,et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[14]  J. Widimský,et al.  Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[15]  X. Jeunemaître,et al.  Bilateral Idiopathic Adrenal Hyperplasia: Genetics and Beyond , 2015, Hormone and Metabolic Research.

[16]  M. Zennaro,et al.  Molecular and Cellular Mechanisms of Aldosterone Producing Adenoma Development , 2015, Front. Endocrinol..

[17]  P. Plouin,et al.  Outcomes of drug-based and surgical treatments for primary aldosteronism. , 2015, Advances in chronic kidney disease.

[18]  G. Rossi,et al.  The molecular basis of primary aldosteronism: from chimeric gene to channelopathy. , 2015, Current opinion in pharmacology.

[19]  J. Bertherat,et al.  mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). , 2014, Human molecular genetics.

[20]  M. D. De Martino,et al.  Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. , 2014, Endocrine-related cancer.

[21]  M. Stowasser,et al.  Role for Germline Mutations and a Rare Coding Single Nucleotide Polymorphism Within the KCNJ5 Potassium Channel in a Large Cohort of Sporadic Cases of Primary Aldosteronism , 2014, Hypertension.

[22]  F. Veglio,et al.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[23]  G. Ning,et al.  The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism , 2013, PloS one.

[24]  D. Morgan,et al.  Hypothalamic mTORC1 signaling controls sympathetic nerve activity and arterial pressure and mediates leptin effects. , 2013, Cell metabolism.

[25]  A. Rosato,et al.  Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. , 2012, Endocrine-related cancer.

[26]  M. D. De Martino,et al.  The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. , 2012, Endocrine-related cancer.

[27]  H. Wallaschofski,et al.  Prevalence of Primary Aldosteronism in Patient’s Cohorts and in Population-based Studies – A Review of the Current Literature , 2011, Hormone and Metabolic Research.

[28]  J. Ceral,et al.  Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients , 2012, European journal of endocrinology.

[29]  E. Lalli,et al.  Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. , 2010, Cancer research.

[30]  D. Rizzoni,et al.  Renal Damage in Primary Aldosteronism: Results of the PAPY Study , 2006, Hypertension.

[31]  M. Novello,et al.  Long-term renal outcomes in patients with primary aldosteronism. , 2006, JAMA.

[32]  M. Ermani,et al.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. , 2006, The Journal of clinical endocrinology and metabolism.

[33]  Yutaka Imai,et al.  European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement , 2003, Journal of hypertension.